BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 9626222)

  • 1. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
    Bigner DD; Brown MT; Friedman AH; Coleman RE; Akabani G; Friedman HS; Thorstad WL; McLendon RE; Bigner SH; Zhao XG; Pegram CN; Wikstrand CJ; Herndon JE; Vick NA; Paleologos N; Cokgor I; Provenzale JM; Zalutsky MR
    J Clin Oncol; 1998 Jun; 16(6):2202-12. PubMed ID: 9626222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.
    Cokgor I; Akabani G; Kuan CT; Friedman HS; Friedman AH; Coleman RE; McLendon RE; Bigner SH; Zhao XG; Garcia-Turner AM; Pegram CN; Wikstrand CJ; Shafman TD; Herndon JE; Provenzale JM; Zalutsky MR; Bigner DD
    J Clin Oncol; 2000 Nov; 18(22):3862-72. PubMed ID: 11078500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
    Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; Cokgor I; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Regalado LV; Sampson JH; Shafman TD; Wikstrand CJ; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
    J Clin Oncol; 2002 Mar; 20(5):1389-97. PubMed ID: 11870184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.
    Brown MT; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Reiman R; Felsberg GJ; Tien RD; Bigner SH; Zalutsky MR; Zhao XG; Wikstrand CJ; Pegram CN; Herndon JE; Vick NA; Paleologos N; Fredericks RK; Schold SC; Bigner DD
    Clin Cancer Res; 1996 Jun; 2(6):963-72. PubMed ID: 9816257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
    Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Gururangan S; Badruddoja M; Dowell JM; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
    J Clin Oncol; 2006 Jan; 24(1):115-22. PubMed ID: 16382120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.
    Bigner DD; Brown M; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Bigner SH; Zhao XG; Wikstrand CJ; Pegram CN
    J Neurooncol; 1995; 24(1):109-22. PubMed ID: 8523067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
    Akabani G; Reardon DA; Coleman RE; Wong TZ; Metzler SD; Bowsher JE; Barboriak DP; Provenzale JM; Greer KL; DeLong D; Friedman HS; Friedman AH; Zhao XG; Pegram CN; McLendon RE; Bigner DD; Zalutsky MR
    J Nucl Med; 2005 Jun; 46(6):1042-51. PubMed ID: 15937318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
    Reardon DA; Quinn JA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Dowell JM; Rich JN; Vredenburgh JJ; Desjardins A; Sampson JH; Gururangan S; Wong TZ; Badruddoja MA; Zhao XG; Bigner DD; Zalutsky MR
    J Nucl Med; 2006 Jun; 47(6):912-8. PubMed ID: 16741299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.
    Lee Y; Bullard DE; Humphrey PA; Colapinto EV; Friedman HS; Zalutsky MR; Coleman RE; Bigner DD
    Cancer Res; 1988 May; 48(10):2904-10. PubMed ID: 2452014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
    Reardon DA; Zalutsky MR; Akabani G; Coleman RE; Friedman AH; Herndon JE; McLendon RE; Pegram CN; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Guruangan S; Boulton S; Raynor RH; Dowell JM; Wong TZ; Zhao XG; Friedman HS; Bigner DD
    Neuro Oncol; 2008 Apr; 10(2):182-9. PubMed ID: 18287339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.
    Akabani G; Reist CJ; Cokgor I; Friedman AH; Friedman HS; Coleman RE; Zhao XG; Bigner DD; Zalutsky MR
    J Nucl Med; 1999 Apr; 40(4):631-8. PubMed ID: 10210222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.
    Akabani G; Cokgor I; Coleman RE; González Trotter D; Wong TZ; Friedman HS; Friedman AH; Garcia-Turner A; Herndon JE; DeLong D; McLendon RE; Zhao XG; Pegram CN; Provenzale JM; Bigner DD; Zalutsky MR
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):947-58. PubMed ID: 10705017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
    Zalutsky MR; Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Wong TZ; Bigner DD
    J Nucl Med; 2008 Jan; 49(1):30-8. PubMed ID: 18077533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies.
    Sampson JH; Akabani G; Friedman AH; Bigner D; Kunwar S; Berger MS; Bankiewicz KS
    Neurosurg Focus; 2006 Apr; 20(4):E14. PubMed ID: 16709019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model.
    Lee YS; Bullard DE; Zalutsky MR; Coleman RE; Wikstrand CJ; Friedman HS; Colapinto EV; Bigner DD
    Cancer Res; 1988 Feb; 48(3):559-66. PubMed ID: 2446747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
    Welt S; Divgi CR; Kemeny N; Finn RD; Scott AM; Graham M; Germain JS; Richards EC; Larson SM; Oettgen HF
    J Clin Oncol; 1994 Aug; 12(8):1561-71. PubMed ID: 8040668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.
    McLendon RE; Akabani G; Friedman HS; Reardon DA; Cleveland L; Cokgor I; Herndon JE; Wikstrand C; Boulton ST; Friedman AH; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2007 May; 34(4):405-13. PubMed ID: 17499730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma.
    Czuczman MS; Straus DJ; Divgi CR; Graham M; Garin-Chesa P; Finn R; Myers J; Old LJ; Larson SM; Scheinberg DA
    J Clin Oncol; 1993 Oct; 11(10):2021-9. PubMed ID: 8410126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate.
    Schuster JM; Garg PK; Bigner DD; Zalutsky MR
    Cancer Res; 1991 Aug; 51(16):4164-9. PubMed ID: 1714341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.
    Mamelak AN; Rosenfeld S; Bucholz R; Raubitschek A; Nabors LB; Fiveash JB; Shen S; Khazaeli MB; Colcher D; Liu A; Osman M; Guthrie B; Schade-Bijur S; Hablitz DM; Alvarez VL; Gonda MA
    J Clin Oncol; 2006 Aug; 24(22):3644-50. PubMed ID: 16877732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.